August 14, 2013
Merck Recommits to State ADAPs Through 2014
Merck, the maker of the HIV drug Isentress (raltegravir), will extend its support of state AIDS Drug Assistance Programs (ADAPs) through the end of 2014, according to a Merck statement. In an agreement with the ADAP Crisis Task Force, Merck will continue supporting programs that provide low-income people with access to HIV medicines; Merck will also allow eligible ADAPs to obtain Isentress film-coated tablets at the same price in effect since January 2012; and it will add a fixed low price to eligible ADAPs for Isentress chewable tablets for children and adolescents with HIV.
To read the statement, click here.
Search: Merck, Isentress, ADAP
Scroll down to comment on this story.
Show comments (0 total)
[Go to top]